Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
You may also be interested in...
Datamonitor projects the newly US FDA-approved esketamine product for treatment-resistant depression will reach sales of almost $2bn in the US, Japan and five major European markets.
Failure of NSI-189 in major depression study sends stock price down about 50% and next steps for development are unclear.
The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders. The allure comes from VA’s strong analytics and data crunching capabilities as well as its investigatory and trial management expertise in high-profile areas like traumatic brain injury, post-traumatic stress and major depression.